Oramed Pharmaceuticals Inc (ORMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $169.59M
Last updated: Nov 17, 2026 at 4:15 PM ET
Oramed Pharmaceuticals Inc (ORMP) P/E Ratio & Valuation History
Oramed Pharmaceuticals (ORMP) trades at 4.2x trailing earnings. Its P/B of 0.5x is below its 5-year median of 0.7x. Its forward P/E is 0.8x.
Current Multiples
Its forward P/E on consensus earnings for the next fiscal year to be reported is below its trailing P/E. Consensus earnings per share are about 425.0% higher than over the last four quarters.
| Multiple | Value |
|---|---|
| P/E (trailing) | 4.2x |
| Forward P/E | 0.8x |
| Price to book | 0.5x |
| PEG | N/A |
| FCF yield | -2.0% |
Historical Medians
Against its 10-year medians, its P/B is 77.3% below 2.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | N/A | N/A | 48.8x |
| P/B | 0.5x | 0.7x | 2.2x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 19.0x in 2018 to 173.2x in 2022.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $2.85 | 1.9x | 58.8x | 0.6x |
| 2024 | $2.42 | N/A | N/A | 0.7x |
| 2023 | $2.31 | 16.5x | 69.2x | 0.6x |
| 2022 | $12.03 | N/A | 173.2x | 3.1x |
| 2021 | $14.28 | N/A | 161.2x | 3.1x |
| 2020 | $4.24 | N/A | 33.5x | 3.6x |
| 2019 | $5.15 | N/A | 33.3x | 5.2x |
| 2018 | $3.00 | N/A | 19.0x | 1.8x |
| 2017 | $9.00 | N/A | 50.4x | 5.6x |
| 2016 | $6.12 | N/A | 64.3x | 3.4x |
Frequently Asked Questions About ORMP
What is ORMP's forward P/E ratio?
Oramed Pharmaceuticals has a forward P/E ratio of 0.8x.
ORMP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors